CSF2 and metastatic melanoma: In one phase II trial, direct intratumoral injection of talimogene laherparepvec (T-VEC), a second-generation oncolytic herpesvirus coding for granulocyte-macrophage colony-stimulating factor (GM-CSF), to 50 patients with unresectable metastatic melanoma achieved 26% response rate (5).